Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
87.40
+4.40 (5.30%)
Feb 21, 2025, 3:00 PM EST
Novo Nordisk Revenue
In the year 2024, Novo Nordisk had annual revenue of 290.40B DKK with 25.03% growth. Novo Nordisk had revenue of 85.68B in the quarter ending December 31, 2024, with 30.09% growth.
Revenue
290.40B DKK
Revenue Growth
+25.03%
P/S Ratio
n/a
Revenue / Employee
3.75M DKK
Employees
77,349
Market Cap
391.83B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 21.77M |
| BioStem Technologies | 210.49M |
Novo Nordisk News
- 2 hours ago - Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm - PRNewsWire
- 3 hours ago - Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk - The Motley Fool
- 22 hours ago - Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - Accesswire
- 22 hours ago - ROSEN, A RESPECTED AND LEADING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO - GlobeNewsWire
- 22 hours ago - A Securities Fraud Lawsuit Has Been Filed Against Novo Nordisk A/S And Investors With Losses Are Urged To Contact The Schall Law Firm - Accesswire
- 22 hours ago - INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO - Accesswire
- 22 hours ago - NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders Have Opportunity to Lead Class Action Lawsuit! - Accesswire
- 22 hours ago - Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO - Accesswire